Last reviewed · How we verify
Anlotinib hydrochloride capsules, Penpulimab injection
Anlotinib hydrochloride capsules, Penpulimab injection is a Multi-target tyrosine kinase inhibitor + PD-1 inhibitor combination Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Advanced non-small cell lung cancer, Other solid tumors (phase 3 evaluation).
Anlotinib is a multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth, while Penpulimab is a PD-1 inhibitor that enhances anti-tumor immune response.
Anlotinib is a multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth, while Penpulimab is a PD-1 inhibitor that enhances anti-tumor immune response. Used for Advanced non-small cell lung cancer, Other solid tumors (phase 3 evaluation).
At a glance
| Generic name | Anlotinib hydrochloride capsules, Penpulimab injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Multi-target tyrosine kinase inhibitor + PD-1 inhibitor combination |
| Target | VEGFR, FGFR, RET, KIT (anlotinib); PD-1 (penpulimab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, RET, KIT) involved in tumor angiogenesis and growth signaling. Penpulimab blocks programmed death receptor-1 (PD-1) on T cells, releasing immune checkpoint inhibition and allowing enhanced anti-tumor immunity. The combination targets both tumor vasculature/growth and immune evasion mechanisms.
Approved indications
- Advanced non-small cell lung cancer
- Other solid tumors (phase 3 evaluation)
Common side effects
- Hypertension
- Fatigue
- Proteinuria
- Hand-foot skin reaction
- Immune-related adverse events (from PD-1 inhibitor)
Key clinical trials
- A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (PHASE1)
- Metastatic Nasopharyngeal Carcinoma (PHASE1)
- Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer (PHASE2)
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (PHASE1)
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (PHASE2)
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. (PHASE3)
- Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anlotinib hydrochloride capsules, Penpulimab injection CI brief — competitive landscape report
- Anlotinib hydrochloride capsules, Penpulimab injection updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about Anlotinib hydrochloride capsules, Penpulimab injection
What is Anlotinib hydrochloride capsules, Penpulimab injection?
How does Anlotinib hydrochloride capsules, Penpulimab injection work?
What is Anlotinib hydrochloride capsules, Penpulimab injection used for?
Who makes Anlotinib hydrochloride capsules, Penpulimab injection?
What drug class is Anlotinib hydrochloride capsules, Penpulimab injection in?
What development phase is Anlotinib hydrochloride capsules, Penpulimab injection in?
What are the side effects of Anlotinib hydrochloride capsules, Penpulimab injection?
What does Anlotinib hydrochloride capsules, Penpulimab injection target?
Related
- Drug class: All Multi-target tyrosine kinase inhibitor + PD-1 inhibitor combination drugs
- Target: All drugs targeting VEGFR, FGFR, RET, KIT (anlotinib); PD-1 (penpulimab)
- Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced non-small cell lung cancer
- Indication: Drugs for Other solid tumors (phase 3 evaluation)
- Compare: Anlotinib hydrochloride capsules, Penpulimab injection vs similar drugs
- Pricing: Anlotinib hydrochloride capsules, Penpulimab injection cost, discount & access